Literature DB >> 13730424

A comparison of the properties of chlorothiazide, spironolactone and a combination of both as diuretic agents.

D A OGDEN, L SCHERR, N SPRITZ, A L RUBIN.   

Abstract

Entities:  

Keywords:  ALDOSTERONE/antagonists; DIURETICS/therapy; HEART FAILURE, CONGESTIVE/therapy; LIVER CIRRHOSIS/therapy

Mesh：

Substances：

Year:  1961        PMID： 13730424     DOI： 10.1056/NEJM196108242650802

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  SPIRONOLACTONE AS AN ADJUVANT TO THE TREATMENT OF CONGESTIVE CARDIAC FAILURE.

Authors:  D W EVANS; C T FLEAR; J G DOMENET
Journal:  Postgrad Med J       Date:  1964-01       Impact factor: 2.401

2.  The aetiology and management of ascites in patients with hepatic cirrhosis: a review.

Authors:  S SHERLOCK; S SHALDON
Journal:  Gut       Date:  1963-06       Impact factor: 23.059

3.  Effectiveness of high-dose spironolactone therapy in patients with chronic liver disease and relatively refractory ascites.

Authors:  J L Campra; T B Reynolds
Journal:  Am J Dig Dis       Date:  1978-11

4.  Progressive hypokalaemia in elderly patients taking three thiazide potassium-sparing diuretic combinations for thirty-six months.

Authors:  N Sawyer; R Gabriel
Journal:  Postgrad Med J       Date:  1988-06       Impact factor: 2.401

5.  Diuretics. II. Other drugs.

Authors: 
Journal:  Br Med J       Date:  1969-07-26

Review 6.  The treatment of heart failure. A methodological review of the literature.

Authors:  G H Guyatt
Journal:  Drugs       Date:  1986-12       Impact factor: 9.546

7.  Spironolactone diuresis in patients with cirrhosis and ascites.

Authors:  R C Eggert
Journal:  Br Med J       Date:  1970-11-14

8.  Metabolic studies on patients with resistant heart failure treated by spironolactone.

Authors:  T A BAYLEY; P G FORBATH; J K WILSON; H P HIGGINS
Journal:  Can Med Assoc J       Date:  1962-12-15       Impact factor: 8.262

9.  Spironolactone is an antagonist of NRG1-ERBB4 signaling and schizophrenia-relevant endophenotypes in mice.

Authors:  Michael C Wehr; Wilko Hinrichs; Magdalena M Brzózka; Tilmann Unterbarnscheidt; Alexander Herholt; Jan P Wintgens; Sergi Papiol; Maria Clara Soto-Bernardini; Mykola Kravchenko; Mingyue Zhang; Klaus-Armin Nave; Sven P Wichert; Peter Falkai; Weiqi Zhang; Markus H Schwab; Moritz J Rossner
Journal:  EMBO Mol Med       Date:  2017-10       Impact factor: 12.137
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.